医疗团体敦促CMS在药品定价政策上谨慎行事. Healthcare groups urge CMS to exercise caution on drug pricing policies.

许多医疗机构和专家敦促医保与医补助服务中心对拟议的药品定价政策采取谨慎行动. Multiple healthcare organizations and experts have urged the Centers for Medicare & Medicaid Services to proceed with caution on proposed drug pricing policies. 他们对维持患者获取,创新和医疗保健系统的可持续性表示担忧. They expressed concerns about maintaining patient access, innovation, and the sustainability of the healthcare system. 包括国家药物委员会,可获得药物的协会和各种健康经济学家在内的团体于2026年3月27日提交了意见,主张对医疗保险优势计划进行透明度,基于证据的决策以及公平补偿. Groups including the National Pharmaceutical Council, the Association for Accessible Medicines, and various health economists submitted comments on March 27, 2026, advocating for transparency, evidence-based decision-making, and fair compensation for Medicare Advantage plans.